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shis has been a remarkable year of advances in heart failure
HF). There have been many achievements, including
pdates of various clinical guidelines (1), formal recognition
f advanced HF and cardiac transplantation as a subspe-
ialty by the American Board of Internal Medicine (2), and
ew findings in a number of clinical trials. In this review, we
ighlight some of the major developments in the field of HF
hat occurred over the past year.
pidemiology
ecent epidemiologic data have drawn attention to the
mportance of preventing HF by implementing lifestyle
odifications long before HF is manifested. The Health
BC (Health Aging, Body, and Composition) study
bserved an incidence of 13.6 cases of HF per 1,000
erson-years in the elderly population, with men and
lack participants being more likely to develop incident
F. Interestingly in this contemporary cohort, a large
roportion of the HF mortality and rehospitalizations
ere associated with modifiable risk factors. This obser-
ation was also made in the Physicians’ Health Study. In
his study of 20,900 middle-age healthy men, those who
ad normal body weight, never smoked, got regular
xercise, drank alcohol in moderation, and consumed
reakfast cereal and fruits and vegetables had an associ-
ted lower lifetime risk of developing HF (3).
Racial and sex differences in the development and pro-
ression of HF have been explored in several publications.
n the Health ABC study, 6 of 8 modifiable risk factors
smoking, increased heart rate, coronary heart disease, left
entricular hypertrophy, uncontrolled blood pressure, and
educed glomerular filtration rate) were more prevalent in
lack participants compared with white participants (4),
specially in the younger patient population (5). It is
larming that up to 1 in 100 black men and women age50
ears may develop HF, with hypertension and renal failure
s the major determinants. However, the strongest deter-
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009, accepted October 25, 2009.inant of prognosis in patients hospitalized for HF was
either race nor sex, but advancing age (6,7).
athophysiology
icroribonucleic acid (miRNA). A growing body of lit-
rature has provided evidence of the potentially important
ole that miRNA may play in the pathophysiology of HF
nd cardiac hypertrophy (8,9). The miRNAs are single-
tranded noncoding ribonucleic acid molecules of 21 to 23
ucleotides in length that are transcribed from the genome,
ut serve to regulate gene expression and cross-talk via
odulation of messenger ribonucleic acid signaling instead
f translation into proteins (10). Differential expressions of
everal miRNAs have been observed between normal and
ardiomyopathy tissues (11), and changes in miRNA ex-
ression have also been observed after ventricular unloading
ith mechanical assist devices (12,13). Because each
iRNA can be linked to an array of downstream processes,
he potential for manipulating such signals to reverse patho-
ogic phenotypes is promising, as has been demonstrated in
roof-of-concept studies (14). In essence, they may provide
otential targets of therapy to delay or reverse cardiac
emodeling or fibrosis.
odified natriuretic peptides. Several important observa-
ions have also emerged regarding the dynamic adaptations
hat occur in HF, particularly regarding the great diversity
f the natriuretic peptide system. An alternative-splicing
rotein modified from B-type natriuretic peptide has been
dentified in patients with advanced HF. These peptides
ave moderate vasodilatory effects, yet provide for preserved
r enhanced renal natriuretic effects (15). Another mutant
trial natriuretic peptide found in humans is noted to be
ssociated with enhanced diuretic, natriuretic, and vasodi-
atory effects relative to the wild-type peptide (16). As
isease progresses, detection of endogenous natriuretic pep-
ides may appear to be reduced in part because of the
resence of alternative forms (many of which have reduced
ioactivity). This may actually represent a relative deficiency
ather than a surplus of natriuretic peptide function (17).
hese observations have greatly expanded our understand-
ng of the importance and diversity of the natriuretic peptide
ystem (either adaptive or maladaptive), and we can expect
ore to come.
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February 16, 2010:688–96 Year in Heart Failuretem cell therapy in HF. Recent interest in the stem cell
eld has involved resident cardiac stem cells that can
ifferentiate into multiple cell types, including cardiac myo-
ytes (18). A small proportion or side population of stem
ells express the cell surface markers Kit and Sca1 (19), and
uch cells can generate cardiomyocytes in vitro and in vivo.
nother side population expresses the transcription factor
sl1, allowing the cell to differentiate into endothelial,
ndocardial, smooth muscle, conduction system, right ven-
ricular, and atrial myogenic lineages during embryonic
eart development (20). The cardiac stem cells can now be
solated and expanded from human myocardial biopsy
amples. So-called induced pluripotent stem cells can be
reated to resemble embryonic stem cells and offer potential
utologous regenerative therapies (21). Such cells require 3
r 4 specific transcription factors (a sort of reprogramming
ocktail) and in principle can generate all mammalian cell
ypes. The processes of isolation, delivery of cells, survival
nd proliferation, electromechanical integration, and stabil-
ty with safety are proving to be a big challenge, but several
ew human protocols are currently underway in the U.S.
nder the National Institutes of Health clinical trials net-
ork model. Despite improvement in our understanding of
he biology, clinical trials to date have provided very modest
esults. Clearly, much more work is needed, both at the
ench and in the clinic.
ew insights in cardiorenal physiology. Observations
rom several groups have verified venous congestion to be an
mportant contributor to the cardiorenal syndrome, both in
table patients with chronic HF (22) as well as in patients
ith advanced HF admitted to the hospital for acute
ecompensation (23). The venous congestion concept is a
omplementary view that accompanies the traditional renal–
rterial underperfusion doctrine. Recognition that increased
ight atrial pressure is driving at least some of the problem
as catalyzed a closer interdisciplinary look at how to best
elieve congestion. A balance of pharmacologic as well as
xtracorporeal fluid removal techniques, particularly when
he natriuretic response to diuretic therapy has diminished
24), has now emerged. Also, tubular function and renal
erfusion have been subjects of interest, with an observed
nverse relation between urinary excretion of amino-
erminal pro–B-type natriuretic peptide (NT-proBNP) and
lasma NT-proBNP, and a direct relation between urinary
xcretion of NT-proBNP and renal plasma flow (indepen-
ent of glomerular filtration) (25).
Meanwhile, the concept of arterial underperfusion has
ot been forgotten, and delivery of natriuretic peptide via a
pecialized catheter has demonstrated enhancement of glo-
erular filtration and urinary sodium excretion (26). Be-
ause the determinants of arterial underperfusion can be
ultifactorial, another important proof-of-concept human
xperiment recently has been performed (27). This new
rocedure was performed using a selective renal sympathetic
blation technique with a localized catheter-based system in
atients with severe, refractory hypertension, which resulted tn a significant and sustained reduction in blood pressure. It
ould be of interest to explore these new techniques in
atients with advanced HF unresponsive to aggressive
iuretic therapy, because renal artery constriction is known
o occur.
valuation of HF
atriuretic peptide testing. One of the most important
dvances this year focused on the possible expanded use of
atriuretic peptide testing to help guide medical therapy in
atients with HF. First, the TIME-CHF (Trial of Inten-
ified versus Standard Medical Therapy in Elderly Patients
ith Congestive Heart Failure) study randomized 499
ubjects 60 years of age to NT-proBNP–guided versus
ymptom-guided therapy. Investigators found no significant
ifferences in survival or all-cause hospitalizations between
he 2 groups, but some benefits were seen in the 60- to
5-year-old age group (28). Similarly, the PRIMA (Effect
f NT-proBNP Guided Treatment of Chronic Heart Fail-
re) study randomized 345 subjects (of 2,900 screened
ospitalized patients with elevated NT-proBNP 1,700
g/ml) to an algorithmic approach that triggered an imme-
iate intensification of HF treatment any time a patient’s
T-proBNP value exceeded an individualized target versus
tandard of care. The NT-proBNP–guided arm did not
how a significant difference in days alive outside the
ospital compared with that guided by symptoms (29).
hese findings are concordant with preliminary results
eported from several smaller single-center studies, and
ighlight the lack of data supporting the use of natriuretic
eptide testing to direct specific therapy. Nevertheless, there
s still great interest in this strategy, with more studies likely
o be done.
The question of how to best interpret natriuretic peptide
evels in patients with HF has been raised by some investi-
ators. In terms of serial measurements, preliminary data
rom the PRIMA study identified that almost 80% of
atients reached their individualized target goal within the
ollow-up period of 1 year after hospital discharge (29).
urthermore, better outcomes were observed among the
8% who maintained NT-proBNP target ranges for 75%
f outpatient visits compared with those who did not
aintain target ranges (29). Clearly, changes in natriuretic
eptide levels can track with long-term prognosis, as illus-
rated in an elegant analysis from the Val-HeFT (Valsartan
n Heart Failure Trial) (30). In clinical practice, there seems
o be a diminishing incremental value as natriuretic peptide
evels rise above a certain threshold, yet only large reduc-
ions (80% decrease) seem to favorably alter the long-term
rognosis in patients with advanced HF (31).
ovel biomarkers. Although many novel biomarkers con-
inue to search for clinical utility, some circulating metabolic
nd nutritional biomarkers that are available in clinical
ractice have been associated with long-term prognosis in
he syndrome of HF. These include low serum estradiol (32)
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Year in Heart Failure February 16, 2010:688–96nd testosterone (33) levels, high serum cobalamin (34)
evels, as well as vitamin D deficiency (35) and low high-
ensity lipoprotein (36) levels, to name a few. Low levels of
oenzyme Q have also been associated with a poor prognosis
n HF (37). In addition, the presence of albuminuria has
een identified as another strong prognostic marker of poor
utcome that may reflect underlying vascular pathobiology.
n a CHARM (Candesartan in Heart Failure: Assessment
f Reduction in Mortality and Morbidity) substudy, the
rine albumin–creatinine ratio was measured at baseline
nd during follow-up of 2,310 patients with HF. Investi-
ators found that 30% had microalbuminuria and 11% had
acroalbuminuria, regardless of impaired or preserved left
entricular function. The presence of any albuminuria was
ndependently predictive of adverse cardiac events (38).
Although the prognostic role of many novel markers such
s ST2 and galectin-3 continues to be explored in HF
39–41), there is more focus on biomarker predictors of HF
evelopment. In an elderly cohort of the Framingham Heart
tudy, high serum leptin levels were associated with in-
reased risk of developing HF, although these levels had
imited prognostic potential beyond clinical variables (42).
n contrast, resistin levels have been predictive of develop-
ent of HF in several cohorts (43,44). Metabolic syndrome
as also been implicated as a risk factor for HF (45). An
mpaired fasting glucose level itself does not seem to be a
trong risk factor for development of HF independent of its
isk for appearance of subsequent diabetes mellitus (46).
yeloperoxidase (47), interleukin-6 (48), and uric acid (49)
ave emerged as predictors of HF development in large
pidemiologic databases. These observations validate to
ome extent the important concept that enhanced oxidative
tress and inflammation may contribute to the development
f HF independent of coronary events.
enetic testing. We have witnessed broader availability of
linical genetic testing for specific cardiomyopathies in
ecent times, which coincides with the 50th anniversary of
he first clinical description of hypertrophic cardiomyopathy
50). With the availability of genetic data, we are beginning
o recognize that different sarcomeric mutations may be
ssociated with different phenotypic expression patterns. In
articular, a more significant disruption of myofilament
rchitecture results from a frame-shift mutation rather than
missense mutation, which may explain different patterns
f diastolic abnormalities with different gene mutations
51). These findings imply that knowledge of specific
utations may someday provide valuable phenotype predic-
ion and possibly even targeted therapeutic considerations.
Practice guidelines regarding genetic evaluation of car-
iomyopathies have been published this year (52). In
eneral, the guidelines have emphasized the strong evidence
hat exists for genetic determinants of hypertrophic cardio-
yopathy and arrhythmogenic right ventricular dysplasia.
n the setting of dilated cardiomyopathy, conduction dis-
ases and arrhythmia may point to specific etiologies, such
s lamin A/C mutations, that portend a poor prognosis (53). ience, considerations for earlier device therapy in such
atients may be warranted (52). It is important to recognize
hat although identification of a specific genetic mutation is
elpful in determining subsequent risks of mutation carriers
mong family members, the absence of any detectable
utation in the genes tested does not imply a truly negative
esult because the causative mutation may be unknown. In
ther words, low test sensitivity remains a hurdle for some
isease conditions. Regardless of phenotype, genetic and
amily counseling is strongly recommended and a compre-
ensive family history must be captured. Education regard-
ng disease transmission and family risk should be provided
52). The guidelines also have highlighted the need for
linical screening, which includes history and physical ex-
mination, echocardiogram, and electrocardiogram, as well
s some specific testing for certain cardiomyopathies, at
egular intervals.
anagement of HF
uideline updates. A broad range of clinical guidelines
rom major professional societies have emerged this year,
ut the new recommendations are more refinements than
ajor overhauls. In both the European and American
uideline updates, broader adoption of natriuretic peptide
esting was recommended based on emerging supportive
ata, even though much emphasis has focused on diagnostic
valuation of patients in the acute setting. There have been
ome upgraded recommendations on the use of add-on
asodilator therapy based on the data from the A-HeFT
African American Heart Failure Trial), with new observa-
ional studies suggesting the potential incremental benefit of
dd-on hydralazine plus isosorbide dinitrate beyond African
mericans (54). Expansion of device therapy also has been
ncorporated, with simplification of inclusion criteria to left
entricular ejection fraction (LVEF) 35%. The emphasis
f rhythm control in patients with HF and atrial fibrillation
as been relaxed based on neutral data from the AF-CHF
Atrial Fibrillation in Congestive Heart Failure) trial (55).
eanwhile, in the absence of positive data, recommenda-
ions regarding the treatment strategies for heart failure
ith preserved ejection fraction (HFpEF) have remained
argely unchanged. Some refinements in diagnostic criteria
egarding the evaluation of diastolic dysfunction have been
roposed by the American Society of Echocardiography
56). The American guidelines have added an expanded
iscussion on the appropriate management of hospitalized
atients with HF, which consists largely of expert opinion
ith the emphasis on maintaining or initiating evidence-
ased pharmacologic therapies during acute exacerbations as
olerated.
evice therapy for HF. Cardiac resynchronization therapy
CRT) continues to be an important treatment for patients
ith advanced HF. The major focus this year has been the
xploration of potential expansion of the standard clinical
ndications. Two important studies have been reported this
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February 16, 2010:688–96 Year in Heart Failureear. First, the 24-month follow-up of the European cohort
f the REVERSE (Resynchronization Reverses Remodel-
ng in Systolic Left Ventricular Dysfunction) trial has
rovided an important demonstration of reverse remodeling
nd clinical improvement using a composite response end
oint. The use of CRT provided a beneficial response in
atients with an LVEF 40% and a QRS duration 120
s but with only mild (New York Heart Association
unctional class I to II) symptoms (57). The likelihood of
eft ventricular reverse remodeling was the highest in those
ith nonischemic etiology or with significant conduction or
echanical delay. The recently published MADIT-CRT
Multicenter Automatic Defibrillator Implantation Trial
ith Cardiac Resynchronization Therapy) demonstrated a
4% relative risk reduction in death or HF events and
everse remodeling with CRT plus defibrillator compared
ith defibrillator alone in 1,820 subjects with LVEF 30%
nd QRS duration 130 ms (Fig. 1). The benefits were
argely driven by reduction in HF events, particularly in
hose with QRS duration 150 ms (58). These landmark
ndings secure the role of CRT as a standard therapy for
atients with significant conduction delays across the symp-
om spectrum of chronic systolic HF. However, unlike drug
herapy, CRT is invasive and expensive; therefore, it may be
ubject to further scrutiny despite the demonstrated clinical
enefits and corresponding reversal of left ventricular re-
odeling. There will likely be some debate in the months
head (both in guideline revisions as well as reimbursement
ecisions) regarding the pros and cons of adopting the
raditional rule of honoring the exact inclusion/exclusion
riteria from the trial evidence, versus stronger endorsement
or only those responder subgroups (i.e., those with wide
RS duration, predominantly 150 ms).
One of the major limitations in device trials has been the
ssumption that once implanted, CRT will deliver an
quivalent benefit regardless of settings or device function-
lities. Optimization of CRT has been widely discussed and
ested with sophisticated imaging techniques, but a stepwise
eview of several simple parameters (such as ensuring
ppropriate lead placement, maximizing percent biventricu-
ar pacing, detecting and treating underlying arrhythmia,
ptimizing atrioventricular delay, as well as providing ap-
ropriate HF disease management) may provide benefit in a
ubgroup of nonresponding CRT patients (59). The ability
f an imaging modality to select the appropriate candidates
or CRT and predict response has been a notion without
irect demonstration (60).
xercise training in HF. Simple assessment of exercise
ndurance continues to be a useful prognostic tool in this
opulation (61), and the lack of improvement after a training
rogram portends a poor prognosis (62). However, the poten-
ial risks and benefits of high-intensity exercise training have
een unclear. Subjects in the National Institutes of Health–
ponsored HF-ACTION (Heart Failure: A Controlled Trial
nvestigating Outcomes of Exercise Training) received either
sual exercise recommendations or a structured program in- dluding 3 months of supervised exercise (40 min 5 times/week)
nd continued aerobic exercise at home thereafter. The pri-
ary results of HF-ACTION showed an overall neutral effect
f an exercise training program on the combined end points of
ortality and HF hospitalizations, but improved overall health
tatus in 2,331 subjects with chronic systolic HF (63,64). The
nvestigators attempted to further analyze the data according to
dherence to a recommended training regimen, and found a
ose–response relationship between regular aerobic exercise
nd patient outcomes (with modest improvement in the
rimary end point of all-cause death or all-cause hospitaliza-
ion, hazard ratio: 0.95, 95% confidence interval: 0.92 to 0.98,
 0.003). The HF-ACTION study provides important
afety reassurance for patients and for physicians in developing
n exercise prescription. In addition, it provides much-needed
ustification for reimbursement of cardiac rehabilitation for this
atient population and highlights the uphill battle to convince
atients to adhere to this aggressive lifestyle modification.
ew insights in the treatment of myocarditis. After a
Figure 1 Primary Results From the MADIT-CRT Trial
Effect of cardiac resynchronization therapy for mild heart failure on the
probability of survival free of heart failure (top) and reverse remodeling
(bottom). Reprinted, with permission, from Moss et al. (58). CRT  cardiac
resynchronization therapy; ICD  implantable cardioverter-defibrillator;
LVEDV  left ventricular end-diastolic volume; LVESV  left ventricular end-
systolic volume.ecade of relatively disappointing results, diagnosis and
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Year in Heart Failure February 16, 2010:688–96anagement of myocarditis remains mostly empirical. After
dvances in the treatment of other viral-mediated diseases,
he potential for reducing viral burden within the myocar-
ium in those patients with so-called viral persistence is still
onsidered a testable hypothesis. In the BICC (Beta-
nterferon in Chronic Viral Cardiomyopathy) trial pre-
ented at the 2008 American Heart Association annual
eeting, improved symptoms and reduced viral load (in-
luding adenovirus, enterovirus, and/or parvovirus) in en-
omyocardial biopsy samples of 143 patients was more
ikely to be associated with beta-interferon treatment than
lacebo. However, there were no differences or changes in
ardiac structure or myocardial performance between
roups, even though beta-interferon therapy appeared safe
65). Because viral persistence has yet to be linked to an
nferior prognosis (66), the benefits of an antiviral thera-
eutic strategy remain in question, particularly with the
eed for invasive evaluation and the high cost of therapy.
Meanwhile, for those patients with no evidence of viral
ersistence, a new randomized study suggests that immuno-
uppression therapy may provide some benefit. In the TIMIC
Tailored Immunosuppression in Inflammatory Cardiomyop-
thy) trial, 85 subjects with chronic left ventricular systolic
ysfunction and evidence of ongoing myocardial inflammation
ere randomized to receive azathioprine plus prednisone
ersus placebo. Additional immunosuppressive therapy was
ssociated with a greater degree of reverse remodeling when
ompared with placebo in addition to at least 6 months of
tandard medical therapy (67). These data are indirectly con-
istent with the positive mechanistic data on reduction of
nfarct size observed with cyclosporine infusion at the time of
ercutaneous coronary intervention during acute myocardial
nfarction (68), illustrating the importance of ongoing immune
ctivity in the progression of cardiac dysfunction.
reating HFpEF. The highly anticipated I-PRESERVE
Irbesartan in Heart Failure with Preserved Ejection Frac-
ion) trial randomized 4,128 patients age 60 years with
ymptomatic HFpEF (LVEF 45%) to receive irbesartan
r placebo. This large and well-executed trial in patients
lready receiving extensive background therapy found no
ncremental benefit of irbesartan in the end points of
ortality or HF hospitalizations (69) (Fig. 2). This was a
isappointing outcome. The findings of I-PRESERVE
ave also reinforced our concept that HFpEF is distinctly
ifferent than systolic HF in ways that are not yet fully
ppreciated.
ulmonary and systemic vasodilators. Expanded indica-
ions for phosphodiesterase 5 inhibitors for moderately
ymptomatic patients with pulmonary hypertension have
een supported by several studies showing improved func-
ional capacity and reduced pulmonary vascular resistance.
eanwhile, the presence of preserved transpulmonary na-
riuretic peptide uptake coupled with diminished cyclic
uanosine monophosphate release has been observed in
atients with pulmonary hypertension associated with left
eart diseases. These observations suggest a relative defi- oiency of downstream mediators of vasodilator response in
atients with increased pulmonary vascular resistance. They
lso support the potential benefit of phosphodiesterase 5
nhibitors or newer soluble guanylate cyclase activators
cinaciguat or BAY 58-2667) in combination with nitric
xide donors (70–72). Several ongoing clinical studies are
xploring the potential therapeutic benefits of such agents.
With the persistent promise of endogenous vasodilator
eptides as potential therapeutic agents, relaxin (a preg-
ancy hormone produced to inhibit uterine contraction that
acilitates the softening and lengthening of the cervix and
he pubic symphysis during childbirth) is being evaluated. In
34 subjects with normal to high blood pressure, intrave-
ous relaxin resulted in rapid and sustained improvement in
yspnea and favorable trends toward improved rates of
ardiovascular death and HF rehospitalization at 60 days
3% to 10% vs. 17%, p  0.06), and lower cardiovascular
eath rates (0 to 6% vs. 14%, p  0.04) within a mean
ollow-up of 4.5 months (73). Further early-phase clinical
rials on this and several other endogenous vasodilator
ompounds will soon be underway.
enal-sparing therapies. The search for renal protective
gents persists, as worsening renal function continues to be
major comorbidity and impediment to effective treatment
or acute decompensated HF. This year we witnessed the
ormal approval of the first oral drug that antagonizes the
asopressin system, tolvaptan. Its role in preserving renal
unction remains largely unclear, but tolvaptan does improve
yponatremia under some conditions. Tolvaptan appears to
enerate an aquaresis without significant hemodynamic
ffects (74). Another promising candidate drug class, aden-
Figure 2 Primary Results of the I-PRESERVE Trial
Primary outcome of death from any cause or hospitalization for pre-specified
cardiovascular causes (worsening heart failure, myocardial infarction, stroke,
atrial or ventricular arrhythmia, or myocardial infarction or stroke occurring dur-
ing hospitalization for any cause). Reprinted, with permission, from Massie et
al. (69).sine A1 receptor antagonists, has encountered major hur-
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February 16, 2010:688–96 Year in Heart Failureles this year. Preliminary results of the PROTECT
Placebo-controlled Randomized Study of the Selective A1
denosine Receptor Antagonist Rolofylline for Patients
ospitalized with Acute Heart Failure and Volume Over-
oad to Assess Treatment Effect on Congestion and Renal
unction Trial) on intravenous rolofylline were announced
t the European Society of Cardiology meeting and indi-
ated no significant differences in major outcomes between
olofylline and placebo using cardiac and renal end points,
espite more symptomatic relief in 2,033 subjects hospital-
zed for HF (75). In particular, rolofylline did not reduce the
ncidence of renal impairment compared with placebo (15%
s. 13.7%), yet showed a trend toward more strokes and
eizures. This class of drugs faces major challenges in further
evelopment.
harmacological inotropic support. Pharmacologic sup-
ort for end-stage (stage D) HF remains a challenge. Once
patient is deemed inotropic-dependent, the prognosis is
oor and the choice of chronic inotropic drug infusions
dobutamine or milrinone) does not seem to affect long-
erm outcomes (76). The search for a safe and effective
asoactive drug continues, and the final publication for the
SSENTIAL (Studies of Oral Enoximone Therapy in
dvanced Heart Failure) trial highlights the challenges in
tudying a drug therapy for this patient population, as
noximone yielded a neutral outcome (77). Meanwhile,
nother approach using a drug called istaroxime that inhib-
ts sodium–potassium adenosine triphosphatase activity
hile stimulating the sarcoplasmic reticulum calcium aden-
sine triphosphatase isoform 2 has been examined in the
ORIZON-HF (Hemodynamic, Echocardiographic, and
eurohormonal Effects of Istaroxime, a Novel Intravenous
notropic and Lusitropic Agent: a Randomized Controlled
rial in Patients Hospitalized with Heart Failure) (78). The
dministration of intravenous istaroxime resulted in rapid
emodynamic improvement with a corresponding reduction
n heart rate and improvement in echocardiographic indexes
f diastolic function. However, like many prior vasoactive
rugs, the road to approval is long and treacherous.
urgical management for advanced HF. Hypothesis 2 of
he STICH (Surgical Treatment for Ischemic Heart Fail-
re) trial was published this year (79). It showed a lack of
enefit for surgical ventricular reconstruction (SVR) (or
odified Dor procedure) in the setting of coronary artery
ypass surgery for patients showing systolic HF (LVEF
35%) and anteroapical dysfunction. This occurred despite
greater reduction in indexed left ventricular systolic
olume in the SVR group. Some proponents of SVR may
till believe that there was a selection bias against enrollment
f those who would benefit from the procedure, whereas
thers postulate that impaired diastolic distensibility caused
y reducing the left ventricular volume may also contribute
o the operation’s lack of benefit. Nevertheless, these rather
isappointing results provide justification for not routinely
erforming SVR at the time of coronary artery bypass
urgery. dovel devices. Several devices tackling novel concepts of
F care have been tested in multicenter clinical trials. The
OMENTUM (Multicenter Trial of the Orqis Medical
ancion System for the Enhanced Treatment of Heart
ailure Unresponsive to Medical Therapy) was published
his year, and indicates relatively neutral findings using a
ovel continuous-flow augmentation device for severe acute
F (80). Results of a multicenter study on the safety and
fficacy of another novel implantable device that delivers
onexcitatory electrical signals during the refractory period
o improve cardiac contractility (cardiac contractility
odulation [CCM]) also were presented this year. The
IX-HF-5 (Evaluation of the Safety and Efficacy of the
PTIMIZER System With Active Fixation Leads in
ubjects With Heart Failure Resulting From Systolic
ysfunction) study randomized 428 patients with advanced
F (LVEF 35% and narrow QRS) to either CCM or no
CM (81), and found that CCM failed to improve the
rimary efficacy outcome of the anaerobic threshold (82).
owever, the investigators observed in a less sick group
New York Heart Association functional class III, LVEF
25%, n  185) that improvement in exercise parameters
nd quality-of-life scores with CCM was possible (82).
lthough only hypothesis-generating, these findings are
uite intriguing because they provide some indication that
his treatment modality requires some reserve for contractile
mprovement. Regardless, exercise parameters are often
ifficult end points for clinical trials to achieve for various
easons that are not well understood.
echanical assist devices and destination therapy. The
pproval of the HeartMate II device (Thoratec Corpora-
ion, Pleasanton, California) as a new-generation nonpul-
atile ventricular assist device (VAD) has paved the way to
much needed advancement in this arena. Long-term
ollow-up of patients with the HeartMate II has provided
eassuring data regarding its long-term safety and reliability
83). However, gastrointestinal and intracranial bleeding
isks have been observed. The nonpulsatile nature of circu-
atory support has even been associated with acquired
oagulopathies in some patients (84). Smaller devices have
lso emerged, although they are still in early clinical devel-
pmental stages (85,86), and pilot studies on less sick
atients are in the planning phases. Questions regarding
ppropriate patient selection, cost effectiveness, periopera-
ive management, and organization of care delivery for
ADs will likely continue to pose important challenges and
eceive ongoing scrutiny (87,88).
isease management. Increasing HF readmission rates
ave been the emerging focus of public reporting as a
urrogate of quality of care and competency (89). It is often
he assumption that many of the readmissions are prevent-
ble, and a major initiative has been launched by the
merican College of Cardiology to reduce the readmissions
ate by 20% in 2012 (the Hospital-to-Home campaign). In
any cases, readmission rates are undeterred by advances inrug and device therapies. Prediction models for readmis-
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Year in Heart Failure February 16, 2010:688–96ions are uniformly inadequate because they do not neces-
arily address many environmental and social factors, and do
ot always precisely characterize disease severity or under-
ying comorbidities (90). There is much debate over meth-
dologies of how to define preventable readmissions and
ppropriateness of adjustments. Therefore, we still lack a
echanism to explore why readmissions occur in individual
atients, which may be a prerequisite for improvement.
emote monitoring remains an attractive concept for dis-
ase management, but demands resources and logistics as
ell as proof of concept. Device-derived data such as
ntrathoracic impedance continue to shed light onto the
linical stability of individual patients (91–93), and even on
he setting of diastolic HF (94). However, like any other
iagnostic tool, studies to gauge efficacy are difficult to
esign, and interpretations of unexplained deviations of
mpedance signals remain a practical challenge.
onclusions
t is refreshing to witness a year of exciting advancements in
F. Although the core drug and device therapeutic ap-
roaches remain largely unchanged, knowledge gained from
his year’s wide range of publications will likely shape the
ocus of research to come. We may see much more focus on
he expanding population of patients with advanced HF
ho may benefit from devices (both CRT and VAD). It
ould be in the form of refining patient selection criteria
using biomarkers or other phenotypes) and exploring strat-
gies for post-procedure optimization. Appropriateness of
esting and therapeutic interventions will likely be scruti-
ized with increasing health care costs and regulations, and
erformance measures will likely be established regardless of
hether there is any direct supporting evidence for their
ffectiveness. That being said, many leads for novel diag-
ostic and therapeutic approaches are maturing, and we
ope in the near future to see advances in early prevention
n the pathogenesis and decompensation of HF.
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